Gene transfer with inducible nitric oxide synthase decreases production of urea by arginase in pulmonary arterial endothelial cells
Authors:
- Louis G. ChicoineLCLouis G. Chicoine
- Tamara L. YoungTYTamara L. Young
- Kristina M. ReberKRKristina M. Reber
- C. Richard LyonsCLC. Richard Lyons
- Yusen LiuYusen Liu
- Leif D. NelinLNLeif D. Nelin
Open Access
- 1 February 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 290 (2) , L298-L306
Abstract
Nitric oxide (NO) is a vasodilator produced from l-arginine (l-Arg) by NO synthase (NOS). Gene therapy for hypertensive disorders has been proposed using the inducible isoform of NOS (iNOS). l-Arg also can be metabolized to urea and l-ornithine (l-Orn) by arginase, and l-Orn can be metabolized to proline and/or polyamines, which are vital for cellular proliferation. To determine the effect of iNOS gene transfer on arginase, we transfected bovine pulmonary arterial endothelial cells (bPAEC) with an adenoviral vector containing the gene for iNOS (AdiNOS). As expected, NO production in AdiNOS bPAEC was substantially greater than in control bPAEC. Although urea production was significantly less in the AdiNOS bPAEC than in the control bPAEC, despite similar levels of arginase I protein, AdiNOS transfection of bPAEC had no effect on the uptake of l-Arg. Inhibiting NO production with Nω-nitro-l-arginine methyl ester increased urea production, and inhibiting urea production with l-valine increased nitrite production, in AdiNOS bPAEC. The addition of l-Arg to the medium increased urea production by AdiNOS bPAEC in a concentration-dependent manner. Thus, in these iNOS-transfected bPAEC, the transfected iNOS and native arginase compete for a common intracellular pool of l-Arg. This competition for substrate resulted in impaired proliferation in the AdiNOS-transfected bPAEC. These findings suggest that the use of iNOS gene therapy for pulmonary hypertensive disorders may not only be beneficial through NO-mediated pulmonary vasodilation but also may decrease vascular remodeling by limiting l-Orn production by native arginase.Keywords
This publication has 43 references indexed in Scilit:
- Intratracheal adenoviral-mediated delivery of iNOS decreases pulmonary vasoconstrictor responses in ratsJournal of Applied Physiology, 2004
- Arginase pathway in human endothelial cells in pathophysiological conditionsJournal of Molecular and Cellular Cardiology, 2004
- Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Arginine availability, arginase, and the immune responseCurrent Opinion in Clinical Nutrition and Metabolic Care, 2003
- Aerosol Gene Transfer With Inducible Nitric Oxide Synthase Reduces Hypoxic Pulmonary Hypertension and Pulmonary Vascular Remodeling in RatsCirculation, 2000
- The Involvement of Tyrosine Kinases, Cyclic AMP/Protein Kinase A, and p38 Mitogen-Activated Protein Kinase in IL-13-Mediated Arginase I Induction in Macrophages: Its Implications in IL-13-Inhibited Nitric Oxide ProductionThe Journal of Immunology, 2000
- Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2000
- Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilizationCellular and Molecular Life Sciences, 1999
- Arginase modulates nitric oxide production in activated macrophagesAmerican Journal of Physiology-Heart and Circulatory Physiology, 1998
- Rebound Pulmonary Hypertension After Inhalation of Nitric OxideThe Annals of Thoracic Surgery, 1996